Porth's Essentials of Pathophysiology, 4e

1048

Genitourinary and Reproductive Function

U N I T 1 1

30. Falcone T, Lebovic DI. Clinical management of endometriosis. Obstet Gynecol. 2011;118:691–705. 31. Bakkum-Gamez J, Gonzalez-Bosquet J, Laack NN, et al. Current issues in the management of endometrial cancer. Mayo Clin Proc. 2008;83(1):97–112. 32. Wright JD, Mendel NIB, Schauli J, et al. Contemporary management of endometrial cancer. Lancet. 2012;379:1352–1360. 33. Buchanan EM, Weinstein LC, Hillson C. Endometrial cancer. Am Fam Physician. 2009;80(10):1075–1989. 34. DiCristofano A, Ellenson LH. Endometrial carcinoma. Annu Rev Pathol Mech Dis. 2007;2:57–85. 35. Evans P, Brunsell S. Uterine fibroid tumors: diagnosis and treatment. Am Fam Physician. 2007;75:1503–1508. 36. Lentz GM. Anatomic defects of the abdominal wall and pelvic floor. In: Lentz GM, Lobo RA, Gershenson DM, et al., eds. Comprehensive Gynecology . 6th ed. Philadelphia, PA: Elsevier Mosby; 2012:453.e3–477.e3. 37. Azziz R. Diagnostic criteria for polycystic ovary syndrome: a reappraisal. Fertil Steril. 2005;83:1343–1346. 38. Goodarzi MO, Dumesic DA, Chazenbath G, et al. (2013). Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 7:219–231. 39. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352:1223–1236. 40. Salmi DJ, Zisser HC, Jovanovic L. Screening for and treatment of polycystic ovary syndrome in teenagers: a mini review. Exp Biol Med. 2004;229:369–377. 41. Roett MA, Evans D. Ovarian cancer. Am Fam Physician. 2009;80(6):609–616. 42. Chobanian N, Dietrich CS. Ovarian cancer. Surg Clin North Am. 2008;88:285–299. 43. Vo C, Carney ME. Ovarian cancer hormonal and environmental risk effect. Obstet Gynecol Clin North Am. 2007;34:687–700. 44. Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer. 2006;109:221–227. 45. Casablanca Y. Management of dysfunctional uterine bleeding. Obstet Gynecol Clin North Am. 2008;35:219–234. 46. Practice Committee of the American Society for Reproductive Medicine. Current evaluation of amenorrhea. Fertil Steril. 2006;86(suppl 4):S148–S155. 47. Morrow C, Naumburg E. Dysmenorrhea. Prim Care Clin Office Pract. 2009;36:10–32. 48. Minkin MJ, Moore AE. Identifying and managing premenstrual disorders: putting strategies into practice. Clin Adv. 2006;(suppl):4–15. 49. Dickerson VM. Premenstrual syndrome and premenstrual dysphoric disorder: individualizing therapy. Fem Patient. 2007;32(1):38–46.

51. Braverman PK. Premenstrual syndrome and premenstrual dysphoric disorder. J Pediatr Adolesc Gynecol. 2007:203–212. 52. Rees M. Management of the menopause: integrated health- care pathway for the menopausal woman. Menopause Int. 2011;17(2):50–54. 53. Lyons J. Advice given to women undergoing gynaecological surgery in relation to menopause, symptoms and hormone replacement therapy: could and should we improve the service we provide? Menopause Int. 2011;17(2):59–62. 54. North American Menopause Society. The 2012 Hormone Therapy Position Statement of the North American Menopause Society. Menopause. 2012;19(3):257–271. 55. Rossouw JE, Manson JE, Kaunitz AM. Lessons learned from the Women’s Health Initiative trials of menopausal hormone therapy. Obstet Gynecol. 2013;121(1):172–176. 56. Gadducci A; Guerrieri ME, Genazzani AR. Benign breast diseases, contraception and hormone replacement therapy. Minerva Ginecol. 2012;64(1):67–74. 57. Lester SC. The breast. In: Kumar V, Abbas AK, Fausto N, et al., eds. Robbins and Cotran Pathologic Basis of Disease . 8th ed. Philadelphia, PA: Saunders Elsevier; 2010:1065–1095. 58. Mulligan AM, O’Malley FP. The breast. In: Rubin R, Strayer DS, eds. Rubin’s Pathology: Clinicopathologic Foundations of Medicine . 6th ed. Philadelphia, PA: Wolters Kluwer Health/ Lippincott Williams & Wilkins; 2012:923–945. 59. Barbieri, R. What is the gynecologist’s role in the care of BRCA previvors? OBG Manage. 2013;25(9):10–14. 60. Hamilton R. Genetics: breast cancer as an exemplar. Nurs Clin North Am. 2009;44(3):327–338. 61. Maughan KL, Lutterbie MA, Ham PS. Treatment of breast cancer. Am Fam Physician. 2009;81(1):1339–1346. 62. American Cancer Society. Detailed guide: breast cancer. 2013. Available at: http://www.cancer.org/acs/groups/cid/documents. Accessed July 10, 2013. 63. Denkert, C, Huober J, Loibl S, et al. HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer. Breast Cancer Res. 2013;15(1):R11. 64. Lønning PE. The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Ann Oncol. 2011;22(3):503–514.

Porth Essentials Resources Explore these additional resources to enhance learning for this chapter: •  NCLEX-Style Questions and Other Resources

on

, http://thePoint.lww.com/PorthEssentials4e

• Study Guide for Essentials of Pathophysiology • Adaptive Learning | Powered by PrepU, http://thepoint.lww.com/ prepu

50. Biggs WS, Demuth RH. Premenstrual syndrome and premenstrual dysphoric disorder. Am Fam Physician. 2011;84(8):918–924.